nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—CYP1A2—Methimazole—Graves' disease	0.2	1	CbGbCtD
Sulindac—Allergic cutaneous angiitis—Propylthiouracil—Graves' disease	0.0441	0.0976	CcSEcCtD
Sulindac—AKR1B1—Metabolism of steroid hormones and vitamin D—GC—Graves' disease	0.0375	0.195	CbGpPWpGaD
Sulindac—Leukocytoclastic vasculitis—Propylthiouracil—Graves' disease	0.0286	0.0633	CcSEcCtD
Sulindac—Neuritis—Methimazole—Graves' disease	0.0221	0.0489	CcSEcCtD
Sulindac—Ageusia—Methimazole—Graves' disease	0.0204	0.045	CcSEcCtD
Sulindac—Neuritis—Propylthiouracil—Graves' disease	0.0188	0.0416	CcSEcCtD
Sulindac—Ageusia—Propylthiouracil—Graves' disease	0.0173	0.0383	CcSEcCtD
Sulindac—AKR1B1—eye—Graves' disease	0.0161	0.104	CbGeAlD
Sulindac—AKR1B1—connective tissue—Graves' disease	0.0155	0.0998	CbGeAlD
Sulindac—Aplastic anaemia—Methimazole—Graves' disease	0.0155	0.0343	CcSEcCtD
Sulindac—PTGDR2—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.0138	0.0716	CbGpPWpGaD
Sulindac—Aplastic anaemia—Propylthiouracil—Graves' disease	0.0132	0.0291	CcSEcCtD
Sulindac—AKR1B1—pituitary gland—Graves' disease	0.012	0.0769	CbGeAlD
Sulindac—AKR1B1—adipose tissue—Graves' disease	0.0119	0.0766	CbGeAlD
Sulindac—MAPK3—eye—Graves' disease	0.0117	0.0751	CbGeAlD
Sulindac—Hepatic failure—Propylthiouracil—Graves' disease	0.0113	0.0251	CcSEcCtD
Sulindac—MAPK3—connective tissue—Graves' disease	0.0113	0.0724	CbGeAlD
Sulindac—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.0108	0.0239	CcSEcCtD
Sulindac—AKR1B1—thyroid gland—Graves' disease	0.0103	0.0663	CbGeAlD
Sulindac—PPARD—adipose tissue—Graves' disease	0.00937	0.0602	CbGeAlD
Sulindac—Neuropathy peripheral—Methimazole—Graves' disease	0.00905	0.02	CcSEcCtD
Sulindac—Jaundice—Methimazole—Graves' disease	0.009	0.0199	CcSEcCtD
Sulindac—MAPK3—pituitary gland—Graves' disease	0.00867	0.0557	CbGeAlD
Sulindac—MAPK3—adipose tissue—Graves' disease	0.00864	0.0555	CbGeAlD
Sulindac—Agranulocytosis—Methimazole—Graves' disease	0.00862	0.019	CcSEcCtD
Sulindac—Hepatitis—Methimazole—Graves' disease	0.00829	0.0183	CcSEcCtD
Sulindac—PPARD—thyroid gland—Graves' disease	0.00811	0.0521	CbGeAlD
Sulindac—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.0077	0.017	CcSEcCtD
Sulindac—Jaundice—Propylthiouracil—Graves' disease	0.00765	0.0169	CcSEcCtD
Sulindac—MAPK3—thyroid gland—Graves' disease	0.00748	0.0481	CbGeAlD
Sulindac—Agranulocytosis—Propylthiouracil—Graves' disease	0.00733	0.0162	CcSEcCtD
Sulindac—Alopecia—Methimazole—Graves' disease	0.00733	0.0162	CcSEcCtD
Sulindac—Hepatitis—Propylthiouracil—Graves' disease	0.00705	0.0156	CcSEcCtD
Sulindac—Vertigo—Methimazole—Graves' disease	0.00648	0.0143	CcSEcCtD
Sulindac—Leukopenia—Methimazole—Graves' disease	0.00646	0.0143	CcSEcCtD
Sulindac—Alopecia—Propylthiouracil—Graves' disease	0.00623	0.0138	CcSEcCtD
Sulindac—Arthralgia—Methimazole—Graves' disease	0.00614	0.0136	CcSEcCtD
Sulindac—Myalgia—Methimazole—Graves' disease	0.00614	0.0136	CcSEcCtD
Sulindac—Dysgeusia—Propylthiouracil—Graves' disease	0.00601	0.0133	CcSEcCtD
Sulindac—Oedema—Methimazole—Graves' disease	0.00589	0.013	CcSEcCtD
Sulindac—Thrombocytopenia—Methimazole—Graves' disease	0.00577	0.0127	CcSEcCtD
Sulindac—Vertigo—Propylthiouracil—Graves' disease	0.00551	0.0122	CcSEcCtD
Sulindac—Leukopenia—Propylthiouracil—Graves' disease	0.00549	0.0121	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00537	0.0119	CcSEcCtD
Sulindac—Paraesthesia—Methimazole—Graves' disease	0.00529	0.0117	CcSEcCtD
Sulindac—Somnolence—Methimazole—Graves' disease	0.00524	0.0116	CcSEcCtD
Sulindac—Arthralgia—Propylthiouracil—Graves' disease	0.00522	0.0115	CcSEcCtD
Sulindac—Myalgia—Propylthiouracil—Graves' disease	0.00522	0.0115	CcSEcCtD
Sulindac—Dyspepsia—Methimazole—Graves' disease	0.00518	0.0115	CcSEcCtD
Sulindac—Oedema—Propylthiouracil—Graves' disease	0.00501	0.0111	CcSEcCtD
Sulindac—Thrombocytopenia—Propylthiouracil—Graves' disease	0.0049	0.0108	CcSEcCtD
Sulindac—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SCGB3A2—Graves' disease	0.00476	0.0247	CbGpPWpGaD
Sulindac—Urticaria—Methimazole—Graves' disease	0.00468	0.0103	CcSEcCtD
Sulindac—Body temperature increased—Methimazole—Graves' disease	0.00466	0.0103	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00456	0.0101	CcSEcCtD
Sulindac—Paraesthesia—Propylthiouracil—Graves' disease	0.0045	0.00994	CcSEcCtD
Sulindac—Somnolence—Propylthiouracil—Graves' disease	0.00445	0.00984	CcSEcCtD
Sulindac—Dyspepsia—Propylthiouracil—Graves' disease	0.00441	0.00974	CcSEcCtD
Sulindac—Pruritus—Methimazole—Graves' disease	0.00417	0.00921	CcSEcCtD
Sulindac—Urticaria—Propylthiouracil—Graves' disease	0.00398	0.00879	CcSEcCtD
Sulindac—Body temperature increased—Propylthiouracil—Graves' disease	0.00396	0.00875	CcSEcCtD
Sulindac—AKR1B1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00385	0.02	CbGpPWpGaD
Sulindac—Vomiting—Methimazole—Graves' disease	0.00374	0.00828	CcSEcCtD
Sulindac—Rash—Methimazole—Graves' disease	0.00371	0.00821	CcSEcCtD
Sulindac—Dermatitis—Methimazole—Graves' disease	0.00371	0.0082	CcSEcCtD
Sulindac—Headache—Methimazole—Graves' disease	0.00369	0.00815	CcSEcCtD
Sulindac—Pruritus—Propylthiouracil—Graves' disease	0.00354	0.00783	CcSEcCtD
Sulindac—Nausea—Methimazole—Graves' disease	0.0035	0.00773	CcSEcCtD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—TNFRSF25—Graves' disease	0.00337	0.0175	CbGpPWpGaD
Sulindac—Vomiting—Propylthiouracil—Graves' disease	0.00318	0.00704	CcSEcCtD
Sulindac—Rash—Propylthiouracil—Graves' disease	0.00316	0.00698	CcSEcCtD
Sulindac—Dermatitis—Propylthiouracil—Graves' disease	0.00315	0.00697	CcSEcCtD
Sulindac—Headache—Propylthiouracil—Graves' disease	0.00314	0.00693	CcSEcCtD
Sulindac—PTGS1—connective tissue—Graves' disease	0.00306	0.0197	CbGeAlD
Sulindac—Nausea—Propylthiouracil—Graves' disease	0.00297	0.00657	CcSEcCtD
Sulindac—PTGS2—connective tissue—Graves' disease	0.00292	0.0188	CbGeAlD
Sulindac—MAPK3—IL-7 Signaling Pathway—IL2RA—Graves' disease	0.00269	0.014	CbGpPWpGaD
Sulindac—CYP1A1—adipose tissue—Graves' disease	0.00267	0.0172	CbGeAlD
Sulindac—MAPK3—CXCR3-mediated signaling events—CXCL10—Graves' disease	0.00252	0.0131	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00251	0.013	CbGpPWpGaD
Sulindac—MAPK3—TSH signaling pathway—TSHR—Graves' disease	0.0025	0.013	CbGpPWpGaD
Sulindac—PTGS1—pituitary gland—Graves' disease	0.00236	0.0151	CbGeAlD
Sulindac—PTGS1—adipose tissue—Graves' disease	0.00235	0.0151	CbGeAlD
Sulindac—CYP1A2—thyroid gland—Graves' disease	0.00234	0.0151	CbGeAlD
Sulindac—CYP1A1—thyroid gland—Graves' disease	0.00231	0.0149	CbGeAlD
Sulindac—PTGS2—pituitary gland—Graves' disease	0.00225	0.0145	CbGeAlD
Sulindac—PTGS2—adipose tissue—Graves' disease	0.00224	0.0144	CbGeAlD
Sulindac—PPARD—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.00218	0.0113	CbGpPWpGaD
Sulindac—PTGDR2—G alpha (i) signalling events—CXCL10—Graves' disease	0.00204	0.0106	CbGpPWpGaD
Sulindac—PTGS1—thyroid gland—Graves' disease	0.00203	0.0131	CbGeAlD
Sulindac—PTGDR2—GPCR ligand binding—TSHR—Graves' disease	0.00191	0.00994	CbGpPWpGaD
Sulindac—MAPK3—IL-2 Signaling Pathway—IL2RA—Graves' disease	0.00177	0.00922	CbGpPWpGaD
Sulindac—MAPK3—Cellular roles of Anthrax toxin—IL1B—Graves' disease	0.00175	0.0091	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—GC—Graves' disease	0.00171	0.0089	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00162	0.00843	CbGpPWpGaD
Sulindac—MAPK3—TSLP Signaling Pathway—IL2RA—Graves' disease	0.00162	0.00843	CbGpPWpGaD
Sulindac—MAPK3—Interleukin-2 signaling—IL2RA—Graves' disease	0.00162	0.00843	CbGpPWpGaD
Sulindac—MAPK3—Interleukin-11 Signaling Pathway—ICAM1—Graves' disease	0.00148	0.0077	CbGpPWpGaD
Sulindac—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—Graves' disease	0.00148	0.00769	CbGpPWpGaD
Sulindac—MAPK3—IL2-mediated signaling events—IL2RA—Graves' disease	0.00145	0.00754	CbGpPWpGaD
Sulindac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—Graves' disease	0.00142	0.00738	CbGpPWpGaD
Sulindac—PPARD—Adipogenesis—FAS—Graves' disease	0.00142	0.00736	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00139	0.00724	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—CD8A—Graves' disease	0.00137	0.00713	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.00132	0.00688	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—B3GNT2—Graves' disease	0.0013	0.00675	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	0.00129	0.0067	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—CD40—Graves' disease	0.00128	0.00664	CbGpPWpGaD
Sulindac—MAPK3—Cellular roles of Anthrax toxin—TNF—Graves' disease	0.00127	0.00661	CbGpPWpGaD
Sulindac—MAPK3—RANKL/RANK Signaling Pathway—ICAM1—Graves' disease	0.00124	0.00645	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	0.00124	0.00642	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—CXCL10—Graves' disease	0.00124	0.00642	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.00122	0.00635	CbGpPWpGaD
Sulindac—MAPK3—IFN-gamma pathway—IFNG—Graves' disease	0.00115	0.00597	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—CXCL10—Graves' disease	0.00114	0.00593	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—TSHR—Graves' disease	0.00108	0.00562	CbGpPWpGaD
Sulindac—MAPK3—Alzheimers Disease—FAS—Graves' disease	0.00108	0.0056	CbGpPWpGaD
Sulindac—PTGS1—Overview of nanoparticle effects—TNF—Graves' disease	0.00107	0.00557	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—CD8A—Graves' disease	0.00107	0.00556	CbGpPWpGaD
Sulindac—MAPK3—IFN-gamma pathway—IL1B—Graves' disease	0.00102	0.00533	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—CXCL10—Graves' disease	0.00102	0.00528	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—CD40—Graves' disease	0.000997	0.00518	CbGpPWpGaD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—FASLG—Graves' disease	0.000997	0.00518	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—TSHR—Graves' disease	0.000981	0.0051	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—FAS—Graves' disease	0.00097	0.00504	CbGpPWpGaD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—FAS—Graves' disease	0.000962	0.005	CbGpPWpGaD
Sulindac—MAPK3—TGF-beta Receptor Signaling—IFNG—Graves' disease	0.000958	0.00498	CbGpPWpGaD
Sulindac—MAPK3—IL2-mediated signaling events—IFNG—Graves' disease	0.000958	0.00498	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.000958	0.00498	CbGpPWpGaD
Sulindac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—Graves' disease	0.000937	0.00487	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000918	0.00477	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—ICAM1—Graves' disease	0.000901	0.00468	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—HLA-E—Graves' disease	0.000894	0.00465	CbGpPWpGaD
Sulindac—MAPK3—ATF-2 transcription factor network—IFNG—Graves' disease	0.000892	0.00464	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—CXCL10—Graves' disease	0.000891	0.00463	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—HLA-E—Graves' disease	0.000873	0.00454	CbGpPWpGaD
Sulindac—PTGS2—Overview of nanoparticle effects—TNF—Graves' disease	0.00085	0.00442	CbGpPWpGaD
Sulindac—MAPK3—IL-1 signaling pathway—IL1B—Graves' disease	0.000842	0.00437	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HLA-E—Graves' disease	0.000841	0.00437	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL2RA—Graves' disease	0.000834	0.00433	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000816	0.00424	CbGpPWpGaD
Sulindac—MAPK3—Regulation of Telomerase—IFNG—Graves' disease	0.000796	0.00414	CbGpPWpGaD
Sulindac—MAPK3—TWEAK Signaling Pathway—TNF—Graves' disease	0.000758	0.00394	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—CXCL10—Graves' disease	0.000698	0.00363	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—HLA-DQB1—Graves' disease	0.000692	0.0036	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—IFNG—Graves' disease	0.000686	0.00356	CbGpPWpGaD
Sulindac—MAPK3—Ceramide signaling pathway—TNF—Graves' disease	0.000681	0.00354	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—ICAM1—Graves' disease	0.000673	0.0035	CbGpPWpGaD
Sulindac—MAPK3—Angiopoietin receptor Tie2-mediated signaling—TNF—Graves' disease	0.000659	0.00343	CbGpPWpGaD
Sulindac—MAPK3—Leptin signaling pathway—IL1B—Graves' disease	0.000657	0.00341	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000638	0.00332	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—CXCL10—Graves' disease	0.000634	0.0033	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—ICAM1—Graves' disease	0.000634	0.00329	CbGpPWpGaD
Sulindac—MAPK3—Alzheimers Disease—IL1B—Graves' disease	0.00063	0.00327	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—HLA-B—Graves' disease	0.000622	0.00323	CbGpPWpGaD
Sulindac—PPARD—Metabolism—GC—Graves' disease	0.00062	0.00322	CbGpPWpGaD
Sulindac—MAPK3—TGF-beta Receptor Signaling—TNF—Graves' disease	0.00062	0.00322	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—CD4—Graves' disease	0.000615	0.00319	CbGpPWpGaD
Sulindac—MAPK3—Cardiac Hypertrophic Response—TNF—Graves' disease	0.000611	0.00317	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—FASLG—Graves' disease	0.000611	0.00317	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000606	0.00315	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—CXCL10—Graves' disease	0.000604	0.00314	CbGpPWpGaD
Sulindac—PPARD—Adipogenesis—TNF—Graves' disease	0.000601	0.00312	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HLA-B—Graves' disease	0.000599	0.00311	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—FAS—Graves' disease	0.000589	0.00306	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-E—Graves' disease	0.000583	0.00303	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000582	0.00302	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TSHR—Graves' disease	0.00058	0.00301	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—HLA-A—Graves' disease	0.000576	0.00299	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000575	0.00299	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—IL1B—Graves' disease	0.000568	0.00295	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000551	0.00286	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—IL2RA—Graves' disease	0.000534	0.00277	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000533	0.00277	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000531	0.00276	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	0.000528	0.00274	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—HLA-DRB1—Graves' disease	0.000526	0.00274	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—ICAM1—Graves' disease	0.000516	0.00268	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000514	0.00267	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000513	0.00266	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IFNG—Graves' disease	0.000512	0.00266	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000506	0.00263	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—ICAM1—Graves' disease	0.000505	0.00263	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL1B—Graves' disease	0.000491	0.00255	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—IFNG—Graves' disease	0.000485	0.00252	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL2RA—Graves' disease	0.000485	0.00252	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—IFNG—Graves' disease	0.000482	0.00251	CbGpPWpGaD
Sulindac—PPARD—Metabolism—B3GNT2—Graves' disease	0.00047	0.00244	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.00047	0.00244	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	0.000462	0.0024	CbGpPWpGaD
Sulindac—MAPK3—Alzheimers Disease—TNF—Graves' disease	0.000457	0.00238	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL1B—Graves' disease	0.000457	0.00238	CbGpPWpGaD
Sulindac—MAPK3—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000435	0.00226	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—IL1B—Graves' disease	0.000433	0.00225	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—IL1B—Graves' disease	0.00043	0.00224	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000423	0.0022	CbGpPWpGaD
Sulindac—PTGS2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000419	0.00218	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IFIH1—Graves' disease	0.000415	0.00216	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-B—Graves' disease	0.000415	0.00216	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—ICAM1—Graves' disease	0.00041	0.00213	CbGpPWpGaD
Sulindac—MAPK3—TNF alpha Signaling Pathway—TNF—Graves' disease	0.000405	0.0021	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	0.000401	0.00208	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—ICAM1—Graves' disease	0.0004	0.00208	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IFNG—Graves' disease	0.000392	0.00204	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.000392	0.00204	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL2RA—Graves' disease	0.000389	0.00202	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—CD4—Graves' disease	0.000386	0.00201	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IFNG—Graves' disease	0.000385	0.002	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-A—Graves' disease	0.000385	0.002	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—IFNG—Graves' disease	0.000384	0.002	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000375	0.00195	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CXCL10—Graves' disease	0.000375	0.00195	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—TNF—Graves' disease	0.000373	0.00194	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000372	0.00193	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000372	0.00193	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000366	0.0019	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.000351	0.00183	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL1B—Graves' disease	0.00035	0.00182	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—IL1B—Graves' disease	0.000345	0.00179	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IL1B—Graves' disease	0.000344	0.00179	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000342	0.00178	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000337	0.00175	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TNF—Graves' disease	0.000332	0.00172	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000328	0.0017	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000327	0.0017	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HLA-E—Graves' disease	0.000327	0.0017	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000316	0.00164	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—TNF—Graves' disease	0.000314	0.00163	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—TNF—Graves' disease	0.000312	0.00162	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IFNG—Graves' disease	0.000312	0.00162	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IFNG—Graves' disease	0.000305	0.00158	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000303	0.00157	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	0.000291	0.00151	CbGpPWpGaD
Sulindac—MAPK3—Disease—B3GNT2—Graves' disease	0.000287	0.00149	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL2RA—Graves' disease	0.000286	0.00149	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—TSHR—Graves' disease	0.000282	0.00146	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IL1B—Graves' disease	0.000278	0.00145	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL1B—Graves' disease	0.000272	0.00141	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000257	0.00133	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TNF—Graves' disease	0.000254	0.00132	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TNF—Graves' disease	0.00025	0.0013	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—TNF—Graves' disease	0.000249	0.0013	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IL2RA—Graves' disease	0.000242	0.00126	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFIH1—Graves' disease	0.000242	0.00126	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000239	0.00124	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GC—Graves' disease	0.000237	0.00123	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000237	0.00123	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000237	0.00123	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HLA-B—Graves' disease	0.000233	0.00121	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.000229	0.00119	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000226	0.00118	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000226	0.00117	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—TNF—Graves' disease	0.000202	0.00105	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNF—Graves' disease	0.000197	0.00102	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-E—Graves' disease	0.00019	0.000989	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GC—Graves' disease	0.000188	0.000979	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD40—Graves' disease	0.000186	0.000967	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTLA4—Graves' disease	0.000183	0.000953	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCL10—Graves' disease	0.000182	0.000946	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—B3GNT2—Graves' disease	0.00018	0.000935	CbGpPWpGaD
Sulindac—PTGS2—Disease—B3GNT2—Graves' disease	0.00017	0.000886	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GC—Graves' disease	0.000167	0.000869	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TSHR—Graves' disease	0.000166	0.000864	CbGpPWpGaD
Sulindac—ALB—Metabolism—GC—Graves' disease	0.000152	0.000792	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DQB1—Graves' disease	0.000151	0.000785	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—B3GNT2—Graves' disease	0.000143	0.000742	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD8A—Graves' disease	0.000141	0.000733	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2RA—Graves' disease	0.000139	0.000723	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CD4—Graves' disease	0.000139	0.000722	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-B—Graves' disease	0.000136	0.000705	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000134	0.000697	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2RA—Graves' disease	0.000127	0.00066	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—B3GNT2—Graves' disease	0.000127	0.000659	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-A—Graves' disease	0.000126	0.000653	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2RA—Graves' disease	0.000117	0.000606	CbGpPWpGaD
Sulindac—MAPK3—Disease—HLA-A—Graves' disease	0.000116	0.000603	CbGpPWpGaD
Sulindac—ALB—Metabolism—B3GNT2—Graves' disease	0.000116	0.0006	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DRB1—Graves' disease	0.000115	0.000597	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ICAM1—Graves' disease	0.00011	0.000573	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL10—Graves' disease	0.000107	0.000559	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GC—Graves' disease	0.000107	0.000554	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—Graves' disease	0.000105	0.000548	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNG—Graves' disease	8.38e-05	0.000436	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2RA—Graves' disease	8.22e-05	0.000427	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD4—Graves' disease	8.1e-05	0.000421	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—B3GNT2—Graves' disease	8.08e-05	0.00042	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1B—Graves' disease	7.48e-05	0.000389	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD4—Graves' disease	7.48e-05	0.000388	CbGpPWpGaD
Sulindac—PTGS2—Disease—HLA-A—Graves' disease	6.9e-05	0.000359	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD4—Graves' disease	4.45e-05	0.000231	CbGpPWpGaD
